MedRhythms, which builds direct stimulation digital therapeutics that use sensors, software, and music to measure and improve walking, announces it has been issued patent US20190022351A1 by the United States Patent and Trademark Office (USPTO).
This is the second granted patent in MedRhythms’ portfolio, the Portand, Maine-based company notes in a media release. The patent, titled “Enhancing Music for Repetitive Motion Activities,” covers the audio engine enabling MedRhythms’ digital therapeutics platform.
This activity follows the previous announcements of a pivotal trial investigating the efficacy of MedRhythms’ pipeline product for improvement of chronic stroke walking deficits, the advancement of the company’s pipeline products, and the creation of Scientific Advisory Boards in stroke, multiple sclerosis and Parkinson’s disease.
This patent covers MedRhythms’ proprietary audio engine and, in doing so, it patents the engine’s ability to both screen and augment songs to make them therapeutically valuable. This is a crucial element in the delivery of the company’s mechanism of action, directly stimulating the human motor system via the auditory system and creating functional outcomes through prescription music, the release explains.
“Building a strong IP portfolio is an integral part of our strategy to build a large, defensible and successful company that makes a big impact in the world. With the granting of this patent, MedRhythms is one step closer to scaling products that improve the lives and mobility of the millions of people around the world with neurologic injuries and diseases,” says Brian Harris, co-founder and CEO of MedRhythms.
This issuance, along with a previously granted patent and several other pending patent applications, demonstrates that the active technology of a digital therapeutic may be protected in a manner similar to that of traditional therapeutics. Moreover, this solidifies the company as one that builds products that directly stimulate the brain to improve clinical outcomes. Related to this intellectual property, MedRhythms is evaluating opportunities for internal development and strategic partnerships to enhance the advancement of its product pipeline, per the release.
[Source(s): MedRhythms, PR Newswire]